Korsana Raises $150M in Series A to Develop Next‑gen Alzheimer’s Antibody

Deal Summary

Korsana, a biotech focused on Alzheimer’s disease, announced a $150 million Series A funding round to advance its next‑generation amyloid‑targeting antibody. The capital will fund clinical development and expansion of its pipeline. Investor identities were not disclosed.